JP5691037B2 - Oily composition - Google Patents
Oily composition Download PDFInfo
- Publication number
- JP5691037B2 JP5691037B2 JP2011540424A JP2011540424A JP5691037B2 JP 5691037 B2 JP5691037 B2 JP 5691037B2 JP 2011540424 A JP2011540424 A JP 2011540424A JP 2011540424 A JP2011540424 A JP 2011540424A JP 5691037 B2 JP5691037 B2 JP 5691037B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- fucoxanthin
- mass
- oil
- oily composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 55
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims description 78
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims description 78
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 23
- 229930003802 tocotrienol Natural products 0.000 claims description 22
- 239000011731 tocotrienol Substances 0.000 claims description 22
- 235000019148 tocotrienols Nutrition 0.000 claims description 22
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 21
- 229960001295 tocopherol Drugs 0.000 claims description 21
- 229930003799 tocopherol Natural products 0.000 claims description 21
- 239000011732 tocopherol Substances 0.000 claims description 21
- 235000010384 tocopherol Nutrition 0.000 claims description 21
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 18
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 16
- -1 L-ascorbic acid fatty acid ester Chemical class 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 9
- 241000199919 Phaeophyceae Species 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 8
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims description 8
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 6
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229940075420 xanthine Drugs 0.000 claims description 2
- 102000006471 Fucosyltransferases Human genes 0.000 claims 1
- 108010019236 Fucosyltransferases Proteins 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 235000021466 carotenoid Nutrition 0.000 description 30
- 150000001747 carotenoids Chemical class 0.000 description 30
- 235000013305 food Nutrition 0.000 description 18
- 238000003860 storage Methods 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 150000003700 vitamin C derivatives Chemical class 0.000 description 5
- 229930002875 chlorophyll Natural products 0.000 description 4
- 235000019804 chlorophyll Nutrition 0.000 description 4
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 235000013793 astaxanthin Nutrition 0.000 description 3
- 239000001168 astaxanthin Substances 0.000 description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 3
- 229940022405 astaxanthin Drugs 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000001746 carotenes Chemical class 0.000 description 3
- 235000005473 carotenes Nutrition 0.000 description 3
- 229930002868 chlorophyll a Natural products 0.000 description 3
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003735 xanthophylls Chemical class 0.000 description 3
- 235000008210 xanthophylls Nutrition 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000980780 Cladosiphon okamuranus Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 241000015177 Saccharina japonica Species 0.000 description 2
- 241001261506 Undaria pinnatifida Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229930002864 chlorophyll c1 Natural products 0.000 description 2
- 229930002865 chlorophyll c2 Natural products 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- QABFXOMOOYWZLZ-UKMVMLAPSA-N epsilon-carotene Chemical compound CC1=CCCC(C)(C)C1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C QABFXOMOOYWZLZ-UKMVMLAPSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- NZEPSBGUXWWWSI-FWFPOGQTSA-N (3e,5e,7e,9e,11e,13e,15e)-18-[(2r,4s)-2,4-dihydroxy-2,6,6-trimethylcyclohexylidene]-1-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15,17-octaen-2-one Chemical compound C([C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)C(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C=C=C1C(C)(C)C[C@H](O)C[C@@]1(C)O NZEPSBGUXWWWSI-FWFPOGQTSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 241000270617 Cheloniidae Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000230129 Eisenia <Phaeophyceae> Species 0.000 description 1
- 241000243681 Eisenia bicyclis Species 0.000 description 1
- 241000068941 Endarachne binghamiae Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000195522 Fucales Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 241000199900 Laminariales Species 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241001465805 Nymphalidae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 241000015203 Saccharina angustata Species 0.000 description 1
- 241001017616 Saccharina diabolica Species 0.000 description 1
- 241001017595 Saccharina longissima Species 0.000 description 1
- 241001017597 Saccharina ochotensis Species 0.000 description 1
- 241000015194 Saccharina religiosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000195475 Sargassaceae Species 0.000 description 1
- 241001260874 Sargassum horneri Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- BIWLELKAFXRPDE-UHFFFAOYSA-N all-trans-zeta-carotene Natural products CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C BIWLELKAFXRPDE-UHFFFAOYSA-N 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000002680 epsilon-carotene Nutrition 0.000 description 1
- QABFXOMOOYWZLZ-UWXQCODUSA-N epsilon-carotene Natural products CC(=CC=CC=C(C)C=CC=C(C)C=C[C@H]1C(=CCCC1(C)C)C)C=CC=C(C)C=C[C@H]2C(=CCCC2(C)C)C QABFXOMOOYWZLZ-UWXQCODUSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- LBCWAKKSVZUJKE-YGQWAKCJSA-N fucoxanthinol Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)CC12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=C=C3C(O)CC(O)CC3(C)C LBCWAKKSVZUJKE-YGQWAKCJSA-N 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- DGNIJJSSARBJSH-NLJAFYFLSA-L magnesium (E)-3-[(3R)-16-ethenyl-11-ethyl-3-methoxycarbonyl-12,17,21,26-tetramethyl-4-oxo-7,24-diaza-23,25-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1(22),2(6),5(26),7,9,11,13,15(24),16,18,20-undecaen-22-yl]prop-2-enoic acid Chemical compound [Mg++].CCc1c(C)c2cc3nc(cc4[n-]c(c(\C=C\C(O)=O)c4C)c4[C@@H](C(=O)OC)C(=O)c5c(C)c(cc1[n-]2)nc45)c(C)c3C=C DGNIJJSSARBJSH-NLJAFYFLSA-L 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Description
本発明は、カロテノイド類を長期間にわたって安定的に含有し得る油性組成物に関する。 The present invention relates to an oily composition that can stably contain carotenoids over a long period of time.
カロテノイド類は、緑色植物やカビ、酵母、キノコ、細菌などが産生する黄〜赤〜紫色の色素成分であり、一般に抗酸化作用を有することが知られている。またカロテノイド類の中には、種々の生理活性を有するものがあり、例えば、ヘマトコッカス藻やクロレラなどの藻類やエビ・カニなどの甲殻類に含まれるアスタキサンチンは、骨粗鬆症や筋萎縮障害に対して効果があることが報告されている(特許文献1および2)。 Carotenoids are yellow-red-purple pigment components produced by green plants, molds, yeasts, mushrooms, bacteria, and the like, and are generally known to have an antioxidant effect. In addition, some carotenoids have various physiological activities. For example, astaxanthin contained in algae such as Haematococcus algae and chlorella and crustaceans such as shrimp and crab is effective against osteoporosis and muscle atrophy disorder. It has been reported that there is an effect (Patent Documents 1 and 2).
また、モズクなどの褐藻類に含まれ下記構造を有するフコキサンチンは、抗腫瘍効果(特許文献3)や神経細胞保護効果(特許文献4)、血糖値上昇抑制効果(特許文献5)、さらに抗肥満効果(非特許文献1および2)等を有することが報告されている。 In addition, fucoxanthin contained in brown algae such as mozuku and having the following structure has an antitumor effect (Patent Document 3), a nerve cell protective effect (Patent Document 4), a blood glucose level increase suppressing effect (Patent Document 5), and an anti-tumor effect. It has been reported to have an obesity effect (Non-patent Documents 1 and 2) and the like.
このようなカロテノイド類の機能性に着目し、カロテノイド類を配合した機能性食品や化粧料が開発されているが、カロテノイド類は構造的に不安定であり、熱や光によって容易に分解、退色してしまうため、食品や化粧料等に安定して配合させることが困難であった。このため、カロテノイド類の保存安定性を向上する方法が検討されており、例えば、プロアントシアニジンを添加する方法(特許文献6)や没食子酸と有機酸類を併用する方法(特許文献7)等が提案されているが、これらの技術は油性組成物中のカロテノイドの安定化には十分なものではなかった。 Focusing on the functionality of these carotenoids, functional foods and cosmetics containing carotenoids have been developed. However, carotenoids are structurally unstable and easily decompose and discolor by heat and light. For this reason, it has been difficult to stably add to foods and cosmetics. For this reason, methods for improving the storage stability of carotenoids have been studied. For example, a method of adding proanthocyanidins (Patent Document 6), a method of combining gallic acid and organic acids (Patent Document 7), etc. are proposed. However, these techniques have not been sufficient to stabilize carotenoids in oily compositions.
従って、カロテノイド類の保存安定性を向上し得る技術の開発が望まれており、本発明は、カロテノイド類を長期間安定して含有し得る組成物を提供することを課題とするものである。 Therefore, development of a technique capable of improving the storage stability of carotenoids is desired, and an object of the present invention is to provide a composition that can stably contain carotenoids for a long period of time.
本発明者らは上記課題を解決するために鋭意研究をした結果、油性基剤として中鎖飽和脂肪酸トリグリセライドを使用し、さらにトコトリエノールを配合することによって、カロテノイド類の分解を著しく抑制し得ることを見出し、本発明を完成させるに至った。 As a result of diligent research to solve the above problems, the present inventors have found that, by using medium-chain saturated fatty acid triglyceride as an oil base and further adding tocotrienol, decomposition of carotenoids can be remarkably suppressed. The headline and the present invention have been completed.
すなわち本発明は、次の成分(A)ないし(C);
(A)カロテノイド類
(B)中鎖飽和脂肪酸トリグリセライド
(C)およびトコトリエノール
を含有することを特徴とするカロテノイド含有油性組成物である。That is, the present invention provides the following components (A) to (C);
(A) Carotenoids (B) A carotenoid-containing oily composition containing (C) medium chain saturated fatty acid triglyceride (C) and tocotrienol.
また本発明は、中鎖飽和脂肪酸トリグリセライドを含有する油性基剤中にカロテノイド類およびトコトリエノールを溶解せしめることを特徴とするカロテノイド類の安定化方法である。 The present invention is also a method for stabilizing carotenoids characterized by dissolving carotenoids and tocotrienol in an oily base containing medium-chain saturated fatty acid triglycerides.
本発明によれば、カロテノイド類の分解を抑制し、保存安定性を著しく向上させることができる。したがって、カロテノイド類の含有量を高く維持し、その抗酸化作用等の生理活性を十分に得ることができるとともに、カロテノイド類の退色を抑制して良好な外観を維持することが可能である。 According to the present invention, decomposition of carotenoids can be suppressed and storage stability can be significantly improved. Accordingly, it is possible to maintain a high carotenoid content and to sufficiently obtain physiological activities such as an antioxidant action, and to maintain a good appearance by suppressing the fading of the carotenoids.
本発明で用いる成分(A)のカロテノイド類には、炭化水素類であるカロテン類及び化学構造中に酸素を含むキサントフィル類が含まれ、具体的には、カロテン類として、α−カロテン、β−カロテン、γ−カロテン、ε―カロテン、リコピン;キサントフィル類として、フコキサンチン、ルテイン、アスタキサンチン、カンタキサンチン、カプサンチン、ゼアキサンチン、アンテラキサンチン、ビオラキサンチン及びそれらのエステル類などの誘導体が例示できる。これらのうち、近年様々な機能性が明らかになりつつあるキサントフィル類が好ましく、中でもフコキサンチン、アスタキサンチンがより好ましく、特にフコキサンチンが好ましく用いられる。 The carotenoids of component (A) used in the present invention include carotenes as hydrocarbons and xanthophylls containing oxygen in the chemical structure. Specifically, as carotenes, α-carotene, β- Examples of carotene, γ-carotene, ε-carotene, lycopene; xanthophylls include derivatives such as fucoxanthin, lutein, astaxanthin, canthaxanthin, capsanthin, zeaxanthin, anthaxanthin, violaxanthin and esters thereof. Of these, xanthophylls whose various functionalities are becoming clear in recent years are preferable, fucoxanthin and astaxanthin are more preferable, and fucoxanthin is particularly preferable.
フコキサンチンは、例えば、ナガマツモ目(Chordaceae)、ヒバマタ目(Fucales)、コンブ目(Laminariales)、カヤノモリ目(Scytosiphonales)等に属する褐藻類等に含まれており、これらを抽出原料として使用することができる。これら褐藻類の中でも、ナガマツモ目のナガマツモ科(Chordaceae)またはモズク科(Spermatochnaceae)、ヒバマタ目のホンダワラ科(Sargassaceae)、コンブ目のコンブ科(Laminariaceae)またはチガイソ科(Alariaceae)、カヤノモリ目のカヤノモリ科(Schtosiphonaceae)等に属する褐藻類が好ましく、前記科に属する褐藻類の中でも、ナガマツモ科のオキナワモズク(Cladosiphon okamuranus)またはモズク科のモズク(Nemacystus decipiens)、ホンダワラ科のホンダワラ(Sargassum fulvellum C.Agardh)、ヒジキ(Hizikia fusiformis)またはアカモク(Sargassum horneri)、コンブ科のアラメ(Eisenia bicyclis (Kjellman) Setchell)、マコンブ(Laminaria japonica)、オニコンブ(Laminaria diabolica)、リシリコンブ(Laminaria ochotensis)、ホソメコンブ(Laminaria religiosa)、ミツイシコンブ(Laminaria angustata)、ナガコンブ(Laminaria longissima)またはガゴメコンブ(Kjellmaniella crassiifolia)、チガイソ科のワカメ(Undaria pinnatifida)、カヤノモリ科のハバノリ(Petalonia binghamiae)が好ましく、特にナガマツモ科のオキナワモズク、モズク科のモズク、カヤノモリ科のハバノリはフコキサンチンを高濃度で含有し、また培養が容易であるために好適に用いられる。 Fucoxanthin is contained in, for example, brown algae belonging to the order of Chloraceae, Fucales, Laminariales, Cytosoniphones, etc., and these can be used as a raw material for extraction. it can. Among these brown algae, the genus Chrysaceae or Chrysaceae, Spermatochaceae, Scarabaceae (Sargassaceae), Crimaceae (Laminariaceae) or Arianoceae (Arianoceae), Brown algae belonging to (Schtosiphonaceae) and the like are preferred, and among the brown algae belonging to the above family, the genus Osalum of the family Nymphalidae (Cladosiphon okamuranus) or the moss (Nemacistus decipiens) of the family A. , Hijiki fusiformis or Akamoku (Sargassum horneri), Eisenia of the kelp family (Eisenia bicyclis (Kjellman) Setchell), Laminaria japonica (Laminaria japonica), Onikonbu (Laminaria diabolica), Rishirikonbu (Laminaria ochotensis), Hosomekonbu (Laminaria religiosa), Mitsuishikonbu (Laminaria angustata), Nagakonbu (Laminaria longissima) or Kagollum combi (Kjellmanella crassiifolia), sea turtle (Undaria pinnatifida), clover (Petalonia binghamiae) Are preferred, especially Nagamatsumo family Cladosiphon okamuranus, the Mozuku family Mozuku, the Habanori of Kayanomori family contains a high concentration of fucoxanthin, also suitably used because it is easy to culture.
また、抽出原料となる褐藻類は、成熟体から遊走子の放出、遊走子から盤状体または糸状体の発生、盤状体または糸状体の着床による直立体の形成、直立体から成熟体への成長という生育サイクルのうちの、盤状体または糸状体〜成熟体の何れの成長段階のものであってもよいが、フコキサンチンを豊富に含むことから盤状体または糸状体が好ましい。なお、盤状体または糸状体は、上記生育サイクルのうちの遊走子と直立体の中間に位置するものであり、別名で呼ばれることもがあるが、本発明においてはこれらの何れも含む。また、盤状体または糸状体は、天然由来のものであっても、人工的に培養されたものを使用してもよく、例えば、特開2004−35528号公報に記載の方法により培養された盤状体または糸状体を用いることができる。 The brown algae used as the raw material for extraction is the release of zoospores from matured bodies, the generation of discoids or filaments from the zoospores, the formation of a solid body by the implantation of a disklike body or a filamentous body, Of the growth cycle of growing into a plate, it may be in any growth stage from a plate-like body or a filamentous body to a mature body, but a plate-like body or a filamentous body is preferred because it contains abundant fucoxanthin. In addition, although a board | plate-like body or a filamentous body is located in the middle of the zoospore and a direct solid in the said growth cycle, and may be called with another name, in the present invention, all of these are included. In addition, the plate-like body or the filamentous body may be naturally derived or artificially cultured, for example, cultured by the method described in JP-A-2004-35528. A board or thread can be used.
上記褐藻類の盤状体または糸状体から、例えば、水、メタノール、エタノール、プロパノール等のアルコール類、アセトン等のケトン類、酢酸エチル等のエステル類、ヘキサン等の脂肪族炭化水素類、ベンゼン等の芳香属炭化水素類、クロロホルム等のハロゲン系有機溶媒、もしくはこれらの混合溶媒を使用してフコキサンチンを抽出する。フコキサンチンは食品等にも使用されることからエタノールもしくは含水エタノールで抽出することが好ましい。含水エタノールは、エタノール:水の混合比が40:60〜99:1、好ましくは80:20〜90:10(質量比)の範囲である。含水エタノールを用いると、クロロフィル等の不純物の含有量が少なく、フコキサンチン等の収率を向上できるために好ましい。これらの溶媒は、盤状体または糸状体に対して10:1〜1:1、好ましくは2:1〜4:1の質量比で添加すれば良い。 From the above-mentioned brown algae plate or filament, for example, water, alcohols such as methanol, ethanol, propanol, ketones such as acetone, esters such as ethyl acetate, aliphatic hydrocarbons such as hexane, benzene, etc. Fucoxanthin is extracted using an aromatic hydrocarbon, a halogen-based organic solvent such as chloroform, or a mixed solvent thereof. Since fucoxanthin is also used for foods and the like, it is preferably extracted with ethanol or hydrous ethanol. Hydrous ethanol has a mixing ratio of ethanol: water of 40:60 to 99: 1, preferably 80:20 to 90:10 (mass ratio). Use of hydrous ethanol is preferable because the content of impurities such as chlorophyll is small and the yield of fucoxanthin and the like can be improved. These solvents may be added at a mass ratio of 10: 1 to 1: 1, preferably 2: 1 to 4: 1, with respect to the disk or filament.
上記溶媒を用いる抽出は常法により行うことができ、例えば、溶媒としてエタノールを用いる場合であれば、15〜60℃、好ましくは20〜40℃の温度で、0.5〜16時間、好ましくは2〜8時間抽出を行えば良い。また、抽出に当たっては、必要により、超音波、攪拌機等により攪拌を行っても良い。 The extraction using the above-mentioned solvent can be performed by a conventional method. For example, when ethanol is used as the solvent, the temperature is 15 to 60 ° C., preferably 20 to 40 ° C., preferably 0.5 to 16 hours, preferably Extraction may be performed for 2 to 8 hours. In extraction, if necessary, stirring may be performed with an ultrasonic wave, a stirrer, or the like.
以上のようにして得られる褐藻類の溶媒抽出物は、フコキサンチンを比較的高濃度で含有しているため、これをそのまま本発明の油性組成物に配合してもよいが、公知の精製手段を用いてさらに精製することにより、フコキサンチンの保存安定性を向上することができる。このような精製手段としては、カラムクロマトグラフィー、液液分配等が例示できるが、抽出物中に含まれるクロロフィル類等の不純物を有効に除去して、保存安定性を向上できることからカラムクロマトグラフィーが好ましい。カラムクロマトグラフィーは、例えば、充填剤としてスチレン−ジビニルベンゼン系、メタアクリル酸エステル系などの逆相系合成吸着樹脂を使用し、吸着画分を水−エタノール系溶媒により溶離させる方法が好適である。カラムクロマトグラフィーによって分画されたフラクションをそのまま使用しても良いが、さらに減圧濃縮等の常法によって、濃縮・溶媒の除去等を行っても良い。このようなカラムクロマトグラフィーを繰り返すことにより、クロロフィル類等の不純物が除去され、フコキサンチンの保存安定性をより向上することができる。クロロフィル類は、溶媒抽出物を0〜10℃程度で冷却し、析出した固形分を濾別することによっても除去することができる。さらに、これらの操作に加え、シリカゲルカラムクロマトグラフィー、再結晶等の操作を繰り返すことにより、例えば、純度90%以上など高純度のフコキサンチンを得ることができる。 Since the solvent extract of brown algae obtained as described above contains fucoxanthin at a relatively high concentration, it may be blended as it is in the oily composition of the present invention. The storage stability of fucoxanthin can be improved by further purification using. Examples of such purification means include column chromatography, liquid-liquid partition, etc., but column chromatography can be used because impurities such as chlorophylls contained in the extract can be effectively removed to improve storage stability. preferable. For column chromatography, for example, a reversed-phase synthetic adsorption resin such as styrene-divinylbenzene or methacrylic acid ester is used as a filler, and the adsorbed fraction is eluted with a water-ethanol solvent. . The fraction fractionated by column chromatography may be used as it is, but further concentration, removal of the solvent, etc. may be performed by a conventional method such as concentration under reduced pressure. By repeating such column chromatography, impurities such as chlorophylls are removed, and the storage stability of fucoxanthin can be further improved. Chlorophylls can also be removed by cooling the solvent extract at about 0 to 10 ° C. and filtering off the precipitated solid. Further, by repeating operations such as silica gel column chromatography and recrystallization in addition to these operations, for example, highly pure fucoxanthin having a purity of 90% or more can be obtained.
本発明の油性組成物における成分(A)の含有量は、1.0〜40.0質量%(以下、単に「%」で示す)、好ましくは3.0〜10.0%である。40.0%よりも多いと成分(B)の油性基剤への溶解性に限界があるため現実的ではない。 The content of the component (A) in the oily composition of the present invention is 1.0 to 40.0% by mass (hereinafter simply indicated by “%”), preferably 3.0 to 10.0%. If it exceeds 40.0%, the solubility of the component (B) in the oil base is limited, which is not realistic.
また本発明の油性組成物には、油性基剤として成分(B)中鎖飽和脂肪酸トリグリセライドを用いる。この中鎖飽和脂肪酸トリグリセライドは、炭素数8〜10の飽和脂肪酸から構成されるものであり、特に長鎖脂肪酸と比較して体脂肪蓄積が少ないため炭素数8のカプリル酸および炭素数10のカプリン酸から構成されるトリ(カプリル/カプリン酸)グリセリルが好適に用いられる。中鎖飽和脂肪酸トリグリセライドの市販品としては、O.D.O、スコレー(いずれもトリ(カプリル/カプリン酸)グリセリル;日清オイリオグループ株式会社製)等が例示できる。中鎖飽和脂肪酸トリグリセライドは、長鎖脂肪酸トリグリセライドに比べ体脂肪蓄積性が低く、肥満予防効果があることが報告されている(Michio Kasai,”Medium−chain fatty acids as Foods for Specified Health Use(FOSHU)”,J.Lipid Nutr.Vol.15,No.1(2006))。 In the oily composition of the present invention, component (B) medium chain saturated fatty acid triglyceride is used as the oily base. This medium-chain saturated fatty acid triglyceride is composed of saturated fatty acids having 8 to 10 carbon atoms, and particularly has less body fat accumulation compared to long-chain fatty acids, so that it has 8 carbon atoms and 10 carbon atoms caprylic acid. Tri (capryl / capric acid) glyceryl composed of an acid is preferably used. Commercially available products of medium chain saturated fatty acid triglycerides include O.D. D. Examples thereof include O and scoley (both are tri (capryl / capric acid) glyceryl; manufactured by Nisshin Oilio Group Co., Ltd.). Medium-chain saturated fatty acid triglycerides are reported to have lower body fat accumulation than long-chain fatty acid triglycerides and have an effect of preventing obesity (Michio Kasai, “Medium-chain fatty acids as Foods for Healthy Health Use (FOSHU)). ", J. Lipid Nutr. Vol. 15, No. 1 (2006)).
本発明の油性組成物における成分(B)の含有量は、好ましくは50.0〜99.0%であり、より好ましくは85.0〜95.0%である。本発明の油性組成物に用いる油性基剤には、この中鎖飽和脂肪酸トリグリセライドに加えて、短鎖脂肪酸トリグリセライド、長鎖脂肪酸トリグリセライド、同様に、ジグリセライド、モノグリセライド等を本発明の効果を損ねない範囲において併用することもできるが、油性基剤全体における中鎖飽和脂肪酸トリグリセライドの含有量は、80.0%以上であることが好ましく、90.0%以上がより好ましく、特に100%であることが好ましい。 Content of the component (B) in the oil-based composition of this invention becomes like this. Preferably it is 50.0-99.0%, More preferably, it is 85.0-95.0%. In addition to the medium-chain saturated fatty acid triglycerides, short-chain fatty acid triglycerides, long-chain fatty acid triglycerides, as well as diglycerides, monoglycerides, and the like are included in the oily base used in the oily composition of the present invention without impairing the effects of the present invention. However, the content of the medium-chain saturated fatty acid triglyceride in the entire oil base is preferably 80.0% or more, more preferably 90.0% or more, and particularly preferably 100%. preferable.
さらに本発明の油性組成物には、成分(C)トコトリエノールを用いる。トコトリエノールには、α、β、γおよびδ−の4つの同族体があるが、本発明ではいずれも使用することができ、またこれらの混合物であってもよい。トコトリエノールの市販品としては、トコリット92(エーザイフードケミカル社製)、オリザトコトリエノールー90(オリザ油化社製)等が挙げられる。 Furthermore, a component (C) tocotrienol is used for the oil-based composition of this invention. There are four homologues of tocotrienol, α, β, γ and δ −, but any of them can be used in the present invention, and a mixture thereof may be used. Examples of commercially available products of tocotrienols include Tocolit 92 (manufactured by Eisai Food Chemical Co., Ltd.) and Orizatocotrienol-90 (manufactured by Oriza Oil Chemical Co., Ltd.).
本発明の油性組成物における成分(C)の含有量は、通常0.1〜6.0%であり、好ましくは0.1〜5.0%であり、より好ましくは0.5〜2.0%である。0.1%よりも低いと十分な効果が得られない場合があり、6.0%よりも高いと油性基剤への溶解が困難になったり、コストの面で好ましくない場合がある。 Content of the component (C) in the oil-based composition of this invention is 0.1-6.0% normally, Preferably it is 0.1-5.0%, More preferably, it is 0.5-2. 0%. If it is lower than 0.1%, a sufficient effect may not be obtained. If it is higher than 6.0%, it may be difficult to dissolve in an oily base, or it may not be preferable in terms of cost.
本発明の油性組成物には、さらに成分(D)トコフェロール(D1)および油溶性ビタミンC誘導体(D2)よりなる群から選ばれる油溶性抗酸化剤を配合することが好ましい。成分(D)の配合により、さらにカロテノイド類の安定性を向上させることができる。トコフェロール(D1)も、α、β、γおよびσ−の4つの同族体があるが、いずれも使用することができ、またこれらの混合物であってもよい。一方、油溶性ビタミンC誘導体(D2)としては、ビタミンCパルミテート、ビタミンCステアレート等のL−アスコルビン酸脂肪酸エステルが挙げられる。本発明では、これらの1種または2種以上を用いることができるが、これらの中でもカロテノイド類の安定化効果に優れるため、ビタミンCパルミテートを用いることが好ましい。 The oil-based composition of the present invention preferably further contains an oil-soluble antioxidant selected from the group consisting of component (D) tocopherol (D1) and oil-soluble vitamin C derivative (D2). By adding the component (D), the stability of the carotenoids can be further improved. As for tocopherol (D1), there are four homologues of α, β, γ and σ −, any of which can be used, or a mixture thereof. On the other hand, examples of the oil-soluble vitamin C derivative (D2) include L-ascorbic acid fatty acid esters such as vitamin C palmitate and vitamin C stearate. In the present invention, one or more of these can be used. Among these, vitamin C palmitate is preferably used because of its excellent carotenoid stabilizing effect.
本発明の油性組成物における成分(D)の配合量は、通常0.1〜7.0%であり、好ましくは0.5〜5.0%であり、より好ましくは0.5〜2.0%である。また、成分(C)トコトリエノールに対する配合質量比は、好ましくは1:50〜50:1(成分(C):成分(D))である。 The compounding quantity of the component (D) in the oil-based composition of this invention is 0.1-7.0% normally, Preferably it is 0.5-5.0%, More preferably, it is 0.5-2. 0%. The blending mass ratio with respect to component (C) tocotrienol is preferably 1:50 to 50: 1 (component (C): component (D)).
成分(D)として、トコフェロール(D1)のみを使用する場合は、成分(C)に対する配合質量比を、1:0.2〜8(成分(C):成分(D1))とすることが好ましく、さらに1:0.8〜5とすることが好ましく、特に1:0.4〜6とすることが好ましい。このような範囲であると、優れたカロテノイド類の安定化効果が得られる。また、油性組成物における成分(C)と成分(D1)の合計の含有量は、通常0.2〜10%、好ましくは1.0〜8.0%、より好ましくは1.0〜4.0%、特に2.0〜4.0%である。この範囲であると、カロテノイド類の安定性が高くなるために好ましい。また、成分(A)カロテノイド類に対する成分(C)および(D1)の合計の配合質量比を1:0.5〜8(成分(A):成分(C)+(D1))とすることが好ましく、1:2〜4とすることがより好ましい。 When only tocopherol (D1) is used as component (D), the blending mass ratio with respect to component (C) is preferably 1: 0.2 to 8 (component (C): component (D1)). Furthermore, it is preferable to set it as 1: 0.8-5, and it is preferable to set it as 1: 0.4-6 especially. Within such a range, an excellent carotenoid stabilizing effect can be obtained. The total content of the component (C) and the component (D1) in the oily composition is usually 0.2 to 10%, preferably 1.0 to 8.0%, more preferably 1.0 to 4. 0%, especially 2.0-4.0%. This range is preferable because the stability of carotenoids is increased. Further, the total blending mass ratio of the components (C) and (D1) to the component (A) carotenoids may be 1: 0.5 to 8 (component (A): component (C) + (D1)). Preferably, 1: 2-4 is more preferable.
また、成分(D)として、トコフェロール(D1)および油溶性ビタミンC誘導体(D2)を併用する場合には、成分(C)に対する配合質量比を、通常1:0.2〜8:0.2〜8、好ましくは、1:0.3〜6:0.4〜5、より好ましくは1:0.4〜5:0.4〜2とすることにより、相乗的なカロテノイド類の安定化効果を得ることができる。また、油性組成物における成分(C)、成分(D1)および成分(D2)の合計の含有量は、通常0.2〜10%、好ましくは1.0〜8.0%、より好ましくは1.0〜4.0%、特に2.0〜4.0%である。この範囲であると、カロテノイド類の安定性が高くなるため好ましい。また、成分(A)カロテノイド類に対する成分(C)、成分(D1)および成分(D2)の合計の配合質量比を1:0.5〜8(成分(A):成分(C)+(D1)+(D2))とすることが好ましく、1:2〜4とすることがより好ましい。さらに、成分(D1)と成分(D2)の配合質量比は、通常1:0.5〜15(成分(D1):成分(D2))であり、好ましくは1:1〜10、より好ましくは1:1〜4である。 Moreover, when using a tocopherol (D1) and an oil-soluble vitamin C derivative (D2) together as a component (D), the compounding mass ratio with respect to a component (C) is usually 1: 0.2-8: 0.2. ~ 8, preferably 1: 0.3 to 6: 0.4 to 5, more preferably 1: 0.4 to 5: 0.4 to 2, thereby synergistically stabilizing carotenoids Can be obtained. Further, the total content of the component (C), the component (D1) and the component (D2) in the oily composition is usually 0.2 to 10%, preferably 1.0 to 8.0%, more preferably 1. 0.0 to 4.0%, particularly 2.0 to 4.0%. This range is preferable because the stability of carotenoids increases. Further, the total blending mass ratio of the component (C), the component (D1) and the component (D2) to the component (A) carotenoids is 1: 0.5 to 8 (component (A): component (C) + (D1 ) + (D2)), more preferably 1: 2-4. Furthermore, the blending mass ratio of the component (D1) and the component (D2) is usually 1: 0.5 to 15 (component (D1): component (D2)), preferably 1: 1 to 10, more preferably 1: 1-4.
本発明の油性組成物には、本発明の効果を損ねない範囲において必要に応じ任意成分を配合することもできる。このような任意成分としては、例えば海藻に由来するにおいをマスキングする目的で、香料、サイクロデキストリン等を用いることができる。 In the oily composition of the present invention, an optional component may be blended as necessary within a range not impairing the effects of the present invention. As such an optional component, for example, a fragrance, a cyclodextrin, or the like can be used for the purpose of masking an odor derived from seaweed.
本発明の油性組成物は、上記成分(A)、(C)および必要に応じ配合する成分(D)を成分(B)を含む油性基剤に常法により混合、溶解させることによって調製することができる。 The oily composition of the present invention is prepared by mixing and dissolving the above components (A), (C) and, if necessary, the component (D) in an oily base containing the component (B) by a conventional method. Can do.
かくして得られる油性組成物は、カロテノイド類の有する抗酸化活性等の効果を期待した飲食品や医薬品、化粧料等に配合することができる。飲食品としては、ソフトカプセル、ハードカプセル、錠剤、顆粒等の形態とした健康食品としたり、他の食品や食品素材に添加して、清涼飲料、ドリンク剤、ゼリー、キャンディー等の飲食品とすることができる。また、公知の医薬担体と組み合わせ、カプセル剤、液剤等の形態とすることができる。一方化粧料としては、常法により、乳液、クリーム、化粧水、ボディージェル等の種々の形態とすることができる。 The oily composition thus obtained can be blended in foods and drinks, pharmaceuticals, cosmetics and the like that are expected to have effects such as antioxidant activity of carotenoids. As foods and drinks, health foods in the form of soft capsules, hard capsules, tablets, granules, etc., or added to other foods and food materials to make foods and drinks such as soft drinks, drinks, jellies, candies, etc. it can. In addition, it can be combined with a known pharmaceutical carrier to form a capsule, liquid, or the like. On the other hand, as cosmetics, various forms such as emulsions, creams, lotions, body gels and the like can be used according to conventional methods.
例えば、カロテノイド類としてフコキサンチンを用いた油性組成物は、上記した抗腫瘍効果、神経細胞保護効果、血糖値上昇抑制効果等を目的とした医薬品等に使用することができる。また、フコキサンチンが有する抗肥満効果に加え、上記したように中鎖脂肪酸トリグリセライドも肥満予防効果を有することから、両者の作用による優れたダイエット食品とすることも可能である。 For example, an oily composition using fucoxanthin as a carotenoid can be used for a pharmaceutical or the like for the above-mentioned antitumor effect, nerve cell protective effect, blood glucose level increase inhibitory effect and the like. In addition to the anti-obesity effect of fucoxanthin, as described above, the medium-chain fatty acid triglyceride also has an obesity-preventing effect, so that it is possible to make an excellent diet food due to the action of both.
以下に、実施例を挙げて本発明をより詳細に説明するが、本発明はこれら実施例に何ら限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples.
製 造 例 1
フコキサンチン濃縮物の調製(1):
特開2004−35528号公報記載の方法に従って培養したオキナワモズク盤状体50kgに150Lの86%エタノール(含水エタノール)を添加し、6時間攪拌抽出を行った。遠心分離により抽出液の固液分離を行い清澄化された抽出液を得た。この抽出液を合成吸着樹脂ダイヤイオンHP−20(三菱化学社製)を充填したカラムにロードし、フコキサンチンを吸着させ、次いで70%エタノール45Lにて洗浄を行った後、90%エタノール120Lにてフコキサンチンを溶出し、フコキサンチン含有画分を得た。このフコキサンチン含有画分を減圧下にて濃縮を行い、フコキサンチン濃縮物を得た。この濃縮物中のフコキサンチン含量を下記条件のHPLCにより定量分析を行ったところ、20%であった。Manufacturing example 1
Preparation of fucoxanthin concentrate (1):
150 L of 86% ethanol (hydrous ethanol) was added to 50 kg of Okinawa mozuku discoids cultured according to the method described in JP-A-2004-35528, followed by extraction with stirring for 6 hours. The clarified extract was obtained by solid-liquid separation of the extract by centrifugation. This extract was loaded onto a column packed with synthetic adsorption resin Diaion HP-20 (Mitsubishi Chemical), adsorbed fucoxanthin, and then washed with 45 L of 70% ethanol, and then into 120 L of 90% ethanol. Fucoxanthin was eluted to obtain a fucoxanthin-containing fraction. This fucoxanthin-containing fraction was concentrated under reduced pressure to obtain a fucoxanthin concentrate. The quantitative analysis of the fucoxanthin content in the concentrate by HPLC under the following conditions was 20%.
(HPLC条件)
高速液体クロマトグラフィーLC−20ABシステム(島津製作所社製)を使用した。カラムはCOSMOSIL 5C22−AR−II(ナカライテスク製、内径4.6x250mm)を用い、移動相はアセトニトリル/水の混合液(80:20)を用いた。フコキサンチンの検出はフォトダイオードアレイにより波長450nmの吸収で行い、流速は1.5ml/minで分析を行った。(HPLC conditions)
A high performance liquid chromatography LC-20AB system (manufactured by Shimadzu Corporation) was used. The column was COSMOSIL 5C 22 -AR-II (manufactured by Nacalai Tesque, inner diameter 4.6 × 250 mm), and the mobile phase was a mixture of acetonitrile / water (80:20). Fucoxanthin was detected by absorption at a wavelength of 450 nm using a photodiode array, and analysis was performed at a flow rate of 1.5 ml / min.
実 施 例 1
フコキサンチン含有油性組成物の調製:
製造例1で得られたフコキサンチン濃縮物に、O.D.O(トリ(カプリル/カプリン酸)グリセリル;日清オイリオ社製)およびトコリット92(トコトリエノール70%、トコフェノール30%;エーザイフードケミカル社製)を、フコキサンチンの終濃度が1%、トコリット92の終濃度が2%になるようにそれぞれ添加して混合した。Example 1
Preparation of fucoxanthin-containing oily composition:
To the fucoxanthin concentrate obtained in Production Example 1, O.D. D. O (tri (capryl / capric acid) glyceryl; manufactured by Nisshin Eulio Co., Ltd.) and Tocolit 92 (Tocotrienol 70%, Tocophenol 30%; manufactured by Eisai Food Chemical Co., Ltd.), fucoxanthin final concentration of 1% Each was added and mixed so that the final concentration was 2%.
比 較 例 1〜11
油性基剤および抗酸化剤を下記表1のように代えた以外は実施例1と同様にして油性組成物を調製した。使用した油性基剤および抗酸化剤は以下のとおりである。
(油性基剤)
O.D.O(トリ(カプリル/カプリン酸)グリセリル;日清オイリオ社製)
キャノーラ油ヘルシーライト(長鎖脂肪酸トリグリセライド;日清オイリオ社製)
オリーブオイル(長鎖脂肪酸トリグリセライド;日清オイリオ社製)
サラダ油(長鎖脂肪酸トリグリセライド;日清オイリオ社製)
(抗酸化剤)
トコリット92(トコトリエノール70%、トコフェロール30%;エーザイフードケミカル社製)
RM−21E(RME;ローズマリー抽出物;三菱化学フーズ社製)
抽出ビタミンE乳液(VE;ミックストコフェロール;三菱化学フーズ社製)Comparative Examples 1-11
An oily composition was prepared in the same manner as in Example 1 except that the oily base and the antioxidant were changed as shown in Table 1 below. The oily base and antioxidant used are as follows.
(Oil base)
O. D. O (tri (caprylic / capric acid) glyceryl; manufactured by Nisshin Oilio Co., Ltd.)
Canola oil healthy light (long chain fatty acid triglyceride; Nisshin Oilio Co., Ltd.)
Olive oil (long-chain fatty acid triglyceride; manufactured by Nisshin Eulio)
Salad oil (long-chain fatty acid triglyceride; Nisshin Oilio Co., Ltd.)
(Antioxidant)
Tokorit 92 (70% tocotrienol, 30% tocopherol; manufactured by Eisai Food Chemical Co., Ltd.)
RM-21E (RME; Rosemary extract; manufactured by Mitsubishi Chemical Foods)
Extracted vitamin E emulsion (VE; mixed tocopherol; manufactured by Mitsubishi Chemical Foods)
試 験 例 1
フコキサンチン保存安定性試験:
実施例1および比較例1〜11で得られた油性組成物をそれぞれ25mlバイアルに入れ、40℃のオーブンに保管した。7日後の油性組成物中のフコキサンチン含量を上記条件によるHPLCで測定した。結果を表1に併せて示す。Test example 1
Fucoxanthin storage stability test:
The oily compositions obtained in Example 1 and Comparative Examples 1 to 11 were each placed in a 25 ml vial and stored in an oven at 40 ° C. The fucoxanthin content in the oily composition after 7 days was measured by HPLC under the above conditions. The results are also shown in Table 1.
7日後のフコキサンチン量は比較例では7〜18%減少しているのに対し実施例1では減少が見られなかった。実施例1と同じ酸化防止剤を添加している比較例3、6、9ではフコキサンチンがそれぞれ9%、18%、9%減少し、実施例1と同じ油性基剤を用いている比較例1、2でもそれぞれ10%、7%減少していることから、実施例1の中鎖飽和脂肪酸トリグリセライドおよびトコトリエノールが特異的に効果の高い組み合わせであることが示された。 The amount of fucoxanthin after 7 days decreased by 7 to 18% in the comparative example, whereas no decrease was observed in Example 1. In Comparative Examples 3, 6, and 9 in which the same antioxidant as in Example 1 was added, fucoxanthin decreased by 9%, 18%, and 9%, respectively, and Comparative Example using the same oily base as in Example 1 Since 1 and 2 also decreased by 10% and 7%, respectively, it was shown that the medium-chain saturated fatty acid triglyceride and tocotrienol of Example 1 are a particularly highly effective combination.
実 施 例 2〜3
油性基剤および抗酸化剤を下記表2のように代えた以外は、実施例1と同様にして油性組成物を調製した。油性組成物を25mlバイアルに入れ、50℃のオーブンおよび−80℃の冷凍庫に保管した。0、1、5、11、15および26日後の油性組成物中のフコキサンチン含量を上記条件によるHPLCで測定した。フコキサンチン含量は、−80℃で同日保管したサンプルを100とした相対値として求めた。結果を表3に示す。Examples 2-3
An oily composition was prepared in the same manner as in Example 1 except that the oily base and the antioxidant were changed as shown in Table 2 below. The oily composition was placed in a 25 ml vial and stored in a 50 ° C. oven and a −80 ° C. freezer. The fucoxanthin content in the oily composition after 0, 1, 5, 11, 15 and 26 days was measured by HPLC under the above conditions. The fucoxanthin content was determined as a relative value with the sample stored on the same day at −80 ° C. as 100. The results are shown in Table 3.
試験1と比べ実施例2、3ではより高温条件下にて長期にわたる加速試験を行っており、これはより長期間の保存安定性を反映している。26日後のフコキサンチン量は実施例3の方が実施例2と比較して10%多く残存していることから、ビタミンCパルミテートを併用することにより、より保存安定性が向上する可能性が示唆された。 Compared with test 1, in Examples 2 and 3, an accelerated test was conducted over a longer period under higher temperature conditions, which reflects a longer storage stability. Since the amount of fucoxanthin after 26 days remained in Example 3 as compared with Example 2 in comparison with Example 2, it was suggested that the storage stability could be further improved by using vitamin C palmitate together. It was done.
実 施 例 4〜7
フコキサンチン含有油性組成物の調製およびフコキサンチン保存安定性試験:
製造例1で得られたフコキサンチン濃縮物に、スコレー64(トリ(カプリル/カプリン酸)グリセリル;日清オイリオ社製)、トコリット92(トコトリエノール70%、トコフェロール30%;エーザイフードケミカル社製)およびトコフェロール(日清オイリオ社製)を、フコキサンチンの終濃度が1%、トコトリエノールとトコフェロールの合計の終濃度が2%になるようにそれぞれ添加して混合した。トコトリエノールとトコフェロールの配合質量比は、1:0.43〜4.7の範囲で変化させた。
得られた油性組成物を25mlバイアルに入れ、40℃のオーブンおよび−80℃の冷凍庫に保管した。15日後の油性組成物中のフコキサンチン含量を上記条件によるHPLCで測定した。フコキサンチン含量は、−80℃で同日保管したサンプルを100とした相対値として求めた。なお、抗酸化剤を添加しないものをコントロールとした。結果を表4に示す。Examples 4-7
Preparation of fucoxanthin-containing oily composition and fucoxanthin storage stability test:
To the fucoxanthin concentrate obtained in Production Example 1, SCORAY 64 (tri (capryl / capric acid) glyceryl; manufactured by Nisshin Oilio Co., Ltd.), Tocorit 92 (70% tocotrienol, 30% tocopherol; manufactured by Eisai Food Chemical Co., Ltd.) and Tocopherol (manufactured by Nisshin Oillio Co., Ltd.) was added and mixed so that the final concentration of fucoxanthin was 1% and the total final concentration of tocotrienol and tocopherol was 2%. The blending mass ratio of tocotrienol and tocopherol was changed in the range of 1: 0.43 to 4.7.
The resulting oily composition was placed in a 25 ml vial and stored in a 40 ° C. oven and a −80 ° C. freezer. The fucoxanthin content in the oily composition after 15 days was measured by HPLC under the above conditions. The fucoxanthin content was determined as a relative value with the sample stored on the same day at −80 ° C. as 100. In addition, the thing which does not add an antioxidant was set as control. The results are shown in Table 4.
表4より、トコトリエノールとトコフェロールを併用することにより、フコキサンチンの安定性が向上することが示された。 From Table 4, it was shown that the stability of fucoxanthin is improved by using tocotrienol and tocopherol in combination.
実施例8〜11、比較例12
フコキサンチン含有油性組成物の調製およびフコキサンチン保存安定性試験:
製造例1で得られたフコキサンチン濃縮物に、スコレー64(トリ(カプリル/カプリン酸)グリセリル;日清オイリオ社製)、トコリット92(トコトリエノール70%、トコフェロール30%;エーザイフードケミカル社製)、トコフェロール(日清オイリオ社製)およびビタミンCパルミテート(三菱フードケミカル社製)を、フコキサンチンの終濃度が1%、トコトリエノール、トコフェロールおよびビタミンCパルミテートの合計の終濃度が1〜8%になるようにそれぞれ添加して混合した。トコトリエノール、トコフェロールおよびビタミンCパルミテートの配合質量比は、1:0.43:0.48〜4.29の範囲で変化させた。
得られた油性組成物を25mlバイアルに入れ、40℃のオーブンおよび−80℃の冷凍庫に保管した。15日後の油性組成物中のフコキサンチン含量を上記条件によるHPLCで測定した。フコキサンチン含量は、−80℃で同日保管したサンプルを100とした相対値として求めた。なお、抗酸化剤を添加しないものをコントロールとした。結果を表5に示す。Examples 8-11, Comparative Example 12
Preparation of fucoxanthin-containing oily composition and fucoxanthin storage stability test:
To the fucoxanthin concentrate obtained in Production Example 1, scoray 64 (tri (capryl / capric acid) glyceryl; manufactured by Nisshin Oilio Co., Ltd.), tocorit 92 (70% tocotrienol, tocopherol 30%; manufactured by Eisai Food Chemical Co., Ltd.), Tocopherol (Nisshin Oilio Co., Ltd.) and Vitamin C palmitate (Mitsubishi Food Chemical Co., Ltd.) so that the final concentration of fucoxanthin is 1%, and the total final concentration of tocotrienol, tocopherol and vitamin C palmitate is 1-8%. Each was added and mixed. The blending mass ratio of tocotrienol, tocopherol and vitamin C palmitate was varied in the range of 1: 0.43: 0.48 to 4.29.
The resulting oily composition was placed in a 25 ml vial and stored in a 40 ° C. oven and a −80 ° C. freezer. The fucoxanthin content in the oily composition after 15 days was measured by HPLC under the above conditions. The fucoxanthin content was determined as a relative value with the sample stored on the same day at −80 ° C. as 100. In addition, the thing which does not add an antioxidant was set as control. The results are shown in Table 5.
表5より、トコトリエノールとトコフェロールに加え、さらにビタミンCパルミテートを用いることにより、相乗的なフコキサンチン安定化効果が得られることが示された。 From Table 5, it was shown that a synergistic fucoxanthin stabilizing effect can be obtained by using vitamin C palmitate in addition to tocotrienol and tocopherol.
製 造 例 2
フコキサンチン濃縮物の調製(2):
(精製1)特開2004−35528号公報記載の方法に従って培養したオキナワモズク盤状体50kgに150Lの86%エタノール(含水エタノール)を添加し、6時間攪拌抽出を行った。遠心分離により抽出液の固液分離を行い清澄化された抽出液を得た。この抽出液を合成吸着樹脂ダイヤイオンHP−20(三菱化学社製)を充填したカラムにロードし、フコキサンチンを吸着させ、次いで70%エタノール45Lにて洗浄を行った後、90%エタノール120Lにてフコキサンチンを溶出し、フコキサンチン含有画分(1)を得た。このフコキサンチン含有画分(1)を減圧下にて濃縮を行い、フコキサンチン濃縮物(1)を得た。この濃縮物について、フコキサンチン含量を製造例1と同様にしてHPLCにより分析した。また、下記条件によるHPLCにより、クロロフィルa、c1、c2の定量分析を行った。結果を表7に示す。Manufacturing example 2
Preparation of fucoxanthin concentrate (2):
(Purification 1) 150 L of 86% ethanol (hydrous ethanol) was added to 50 kg of Okinawa mozuku discoids cultured according to the method described in JP-A No. 2004-35528, followed by stirring and extraction for 6 hours. The clarified extract was obtained by solid-liquid separation of the extract by centrifugation. This extract was loaded onto a column packed with synthetic adsorption resin Diaion HP-20 (Mitsubishi Chemical), adsorbed fucoxanthin, and then washed with 45 L of 70% ethanol, and then into 120 L of 90% ethanol. Fucoxanthin was eluted to obtain a fucoxanthin-containing fraction (1). This fucoxanthin-containing fraction (1) was concentrated under reduced pressure to obtain a fucoxanthin concentrate (1). About this concentrate, the fucoxanthin content was analyzed by HPLC in the same manner as in Production Example 1. In addition, chlorophyll a, c 1 and c 2 were quantitatively analyzed by HPLC under the following conditions. The results are shown in Table 7.
(HPLC条件)
高速液体クロマトグラフィーLC−20ABシステム(島津製作所社製)を使用した。カラムはIntersil ODS−P 5μm(GLサイエンス製、内径4.6x150mm)を用いた。流速は0.8ml/min.で、分析はグラジエントにて行った。
溶媒A:メタノール(0.25M酢酸アンモニウム含有),アセトニトリル,水=4:3.5:2.5
溶媒B:アセトニトリル,酢酸エチル=3:7
グラジエント分析のタイムプログラムは下記表6の通りである。(HPLC conditions)
A high performance liquid chromatography LC-20AB system (manufactured by Shimadzu Corporation) was used. As the column, Intersil ODS-P 5 μm (GL Science, inner diameter 4.6 × 150 mm) was used. The flow rate is 0.8 ml / min. The analysis was performed with a gradient.
Solvent A: methanol (containing 0.25M ammonium acetate), acetonitrile, water = 4: 3.5: 2.5
Solvent B: acetonitrile, ethyl acetate = 3: 7
The time program for gradient analysis is shown in Table 6 below.
(精製2)上記フコキサンチン含有画分(1)にエタノール濃度が70%になるようにRO水を添加し、この抽出液を合成吸着樹脂ダイヤイオンHP−20を充填したカラムにロードし、フコキサンチンを吸着させ、次いで70%エタノール45Lにて洗浄を行った後、90%エタノール90Lにてフコキサンチンを溶出し、フコキサンチン含有画分(2)を得た。このフコキサンチン含有画分(2)を減圧下にて濃縮を行い、フコキサンチン濃縮物(2)を得た。この濃縮物中のフコキサンチンおよびクロロフィルa、c1、c2の含量について、上記と同様にして定量分析を行った。結果を表7に示す。(Purification 2) RO water is added to the fucoxanthin-containing fraction (1) so that the ethanol concentration becomes 70%, and this extract is loaded onto a column packed with synthetic adsorption resin Diaion HP-20. After xanthine was adsorbed and washed with 45 L of 70% ethanol, fucoxanthin was eluted with 90 L of 90% ethanol to obtain a fucoxanthin-containing fraction (2). This fucoxanthin-containing fraction (2) was concentrated under reduced pressure to obtain a fucoxanthin concentrate (2). The contents of fucoxanthin and chlorophyll a, c 1 and c 2 in this concentrate were quantitatively analyzed in the same manner as described above. The results are shown in Table 7.
カラム精製を2回繰り返すことにより、フコキサンチンの純度が24%になり、またクロロフィルc1は17%、c2は32%それぞれ減少し、aはほぼ完全に除去された。By repeating the column purification twice, the purity of fucoxanthin was 24%, chlorophyll c 1 was reduced by 17%, c 2 was reduced by 32%, and a was almost completely removed.
実施例12〜14
フコキサンチン含有油性組成物の調製およびフコキサンチン保存安定性試験(耐光性):
製造例2で得られたフコキサンチン濃縮物(1)および(2)に、スコレー64(トリ(カプリル/カプリン酸)グリセリル;日清オイリオ社製)、トコリット92(トコトリエノール70%、トコフェロール30%;エーザイフードケミカル社製)、を、フコキサンチンの終濃度が1%、トコトリエノールの終濃度が2%になるようにそれぞれ添加して混合した(実施例12および13)。また、フコキサンチン濃縮物に代えて、試薬(和光純薬工業社製、純度94.0%以上)を用いて同様の組成で油性組成物を調製した(実施例14)。
得られた油性組成物を25mlバイアルに入れ、5000Lux、40℃の条件下で保存し、0、4、5、6、7日後における油性組成物中のフコキサンチン含量を上記製造例1の条件によるHPLCで測定した。フコキサンチン含量は、−80℃で同日保管したサンプルを100とした相対値として求めた。結果を表8に示す。Examples 12-14
Preparation of fucoxanthin-containing oily composition and fucoxanthin storage stability test (light resistance):
To the fucoxanthin concentrates (1) and (2) obtained in Production Example 2, scoray 64 (tri (capryl / capric acid) glyceryl; manufactured by Nisshin Oilio Co., Ltd.), tocorit 92 (tocotrienol 70%, tocopherol 30%; Eisai Food Chemical Co., Ltd.) was added and mixed such that the final concentration of fucoxanthin was 1% and the final concentration of tocotrienol was 2% (Examples 12 and 13). Moreover, it replaced with the fucoxanthin concentrate and prepared the oil-based composition with the same composition using the reagent (The Wako Pure Chemical Industries Ltd. make, purity 94.0% or more) (Example 14).
The obtained oily composition was put in a 25 ml vial and stored under conditions of 5000 Lux and 40 ° C., and the fucoxanthin content in the oily composition after 0, 4, 5, 6, and 7 days was determined according to the conditions of Production Example 1 above. Measured by HPLC. The fucoxanthin content was determined as a relative value with the sample stored on the same day at −80 ° C. as 100. The results are shown in Table 8.
カラム精製を2回繰り返すことにより、7日後の安定性が11%改善された。クロロフィルa等の不純物の除去がフコキサンチンの保存安定性に有効であると考えられる。 By repeating the column purification twice, the stability after 7 days was improved by 11%. It is considered that removal of impurities such as chlorophyll a is effective for the storage stability of fucoxanthin.
実 施 例 15
フコキサンチンソフトカプセルの調製:
下記処方のソフトカプセルを調製した。
(処方) (1カプセル400mgあたり)
(1)ゼラチン(皮膜) 150mg
(2)実施例1の油性組成物 250mg
合計 400mg
このソフトカプセルは保存安定性に優れるものである。Example 15
Preparation of fucoxanthin soft capsule:
A soft capsule having the following formulation was prepared.
(Prescription) (per 400mg capsule)
(1) Gelatin (film) 150mg
(2) 250 mg of the oily composition of Example 1
400mg total
This soft capsule has excellent storage stability.
実 施 例 16
フコキサンチン含有飲料の調製:
下記処方の飲料を調製した。
(処方) (100mlあたり)
(1)実施例1の油性組成物 0.5g
(2)レシチン(大豆由来) 0.5g
(3)緑茶抽出物(三共ライフテック) 0.85g
(4)果糖 4g
(5)L-アスコルビン酸 0.05g
(6)香料 0.1g
(7)精製水
合計 100g(精製水で100gとする)
この飲料は保存安定性に優れるものである。Example 16
Preparation of fucoxanthin-containing beverage:
A beverage having the following formulation was prepared.
(Prescription) (per 100ml)
(1) Oily composition of Example 1 0.5 g
(2) Lecithin (derived from soybean) 0.5g
(3) Green tea extract (Sankyo Lifetech) 0.85g
(4) Fructose 4g
(5) L-ascorbic acid 0.05g
(6) Fragrance 0.1g
(7) Purified water
100g in total (100g with purified water)
This beverage is excellent in storage stability.
本発明の油性組成物は、カロテノイド類を長期間にわたって安定的に保持できるため、健康食品や医薬品等に用いる原料として極めて有用である。 Since the oily composition of the present invention can stably hold carotenoids over a long period of time, it is extremely useful as a raw material for use in health foods and pharmaceuticals.
Claims (9)
(A)フコキサンチン 1.0〜3.0質量%
(B)トリ(カプリル/カプリン酸)グリセリル 85.0〜95.0質量%
(C)トコトリエノール 0.1〜5.0質量%
(D)トコフェロール(D1)およびL−アスコルビン酸脂肪酸エステル(D2)より
なる群から選ばれる1種または2種以上の油溶性抗酸化剤 0.5〜5.0質量%
を含有し、成分(C)と成分(D)の配合質量比が、1:50〜50:1であることを特徴とする油性組成物。 The following components (A) to ( D );
(A) Fucoxanthin 1.0-3.0 mass%
(B) Tri (capryl / capric acid) glyceryl 85.0-95.0 mass%
(C) Tocotrienol 0.1-5.0% by mass
(D) From tocopherol (D1) and L-ascorbic acid fatty acid ester (D2)
One or more oil-soluble antioxidants selected from the group consisting of 0.5 to 5.0% by mass
And the blending mass ratio of the component (C) and the component (D) is 1:50 to 50: 1 .
が、1:0.2〜8である請求項1記載の油性組成物。 A component (D) is tocopherol (D1), mixing mass ratio of component (C) and the component (D1) is 1: claim 1 oleaginous composition wherein 0.2 to 8.
(A)フコキサンチン 1.0〜3.0質量%
(B)トリ(カプリル/カプリン酸)グリセリル 85.0〜95.0質量%
(C)トコトリエノール 0.1〜5.0質量%
(D)トコフェロール(D1)およびL−アスコルビン酸脂肪酸エステル(D2)より
なる群から選ばれる1種または2種以上の油溶性抗酸化剤 0.5〜5.0質量%
を含有し、成分(C)と成分(D)の配合質量比が、1:50〜50:1である油性組成物において、トリ(カプリル/カプリン酸)グリセリルを含有する油性基剤中にフコキサンチン、トコトリエノールおよび油溶性抗酸化剤を溶解せしめることを特徴とする油性組成物中のフコキサンチンの安定化方法。 The following components (A) to (D);
(A) Fucoxanthin 1.0-3.0 mass%
(B) Tri (capryl / capric acid) glyceryl 85.0-95.0 mass%
(C) Tocotrienol 0.1-5.0% by mass
(D) From tocopherol (D1) and L-ascorbic acid fatty acid ester (D2)
One or more oil-soluble antioxidants selected from the group consisting of 0.5 to 5.0% by mass
Containing, the mixing mass ratio of component (C) and the component (D), 1: 50 to 50: In the oil-based composition is 1, fucosyltransferase in an oil base containing a tri (caprylate / caprate), glyceryl A method for stabilizing fucoxanthin in an oily composition, comprising dissolving xanthine, tocotrienol and an oil-soluble antioxidant .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011540424A JP5691037B2 (en) | 2009-11-10 | 2010-05-10 | Oily composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009256746 | 2009-11-10 | ||
JP2009256746 | 2009-11-10 | ||
JP2011540424A JP5691037B2 (en) | 2009-11-10 | 2010-05-10 | Oily composition |
PCT/JP2010/057878 WO2011058773A1 (en) | 2009-11-10 | 2010-05-10 | Oil-based composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2011058773A1 JPWO2011058773A1 (en) | 2013-03-28 |
JP5691037B2 true JP5691037B2 (en) | 2015-04-01 |
Family
ID=43991437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011540424A Expired - Fee Related JP5691037B2 (en) | 2009-11-10 | 2010-05-10 | Oily composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5691037B2 (en) |
WO (1) | WO2011058773A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018512432A (en) * | 2015-04-13 | 2018-05-17 | アルガテクノロジーズ リミテッドAlgatechnologies Ltd. | Compositions containing carotenoids and uses thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012133246A1 (en) * | 2011-03-30 | 2012-10-04 | 富士フイルム株式会社 | Carotenoid-containing composition and method for producing same |
JP5711616B2 (en) * | 2011-06-09 | 2015-05-07 | キッコーマン株式会社 | IL-17 production inhibitor |
JP6771853B2 (en) * | 2014-03-31 | 2020-10-21 | 小林製薬株式会社 | Vitamin B6 containing composition |
JP6395452B2 (en) * | 2014-06-05 | 2018-09-26 | 花王株式会社 | Topical skin preparation |
FR3032879B1 (en) * | 2015-02-24 | 2018-04-06 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | OBTAINING EXTRACT OF GAMETOPHYTES FROM BROWN ALGAE AND USE THEREOF AS ACTIVE ANTI-AGING COSMETIC PRINCIPLE |
JP2017046688A (en) * | 2015-08-31 | 2017-03-09 | 株式会社みやぎヘルスイノベーション | Beverage composition for weight gain inhibition |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002218994A (en) * | 2001-01-26 | 2002-08-06 | Fuji Chem Ind Co Ltd | Method for purifying crude xanthophyll |
JP2004035528A (en) * | 2002-07-08 | 2004-02-05 | Tropical Technology Center Ltd | Method for acquiring fucoxanthin and/or fucosterol |
WO2005054415A1 (en) * | 2003-12-02 | 2005-06-16 | Suntory Limited | Fat composition containing phospholipid and long-chain polyunsaturated fatty acid-supplying compound and food using the same |
WO2007079443A2 (en) * | 2006-01-03 | 2007-07-12 | The Texas A & M University System | Bioactive complex compositions and methods of use thereof |
JP2007538040A (en) * | 2004-05-18 | 2007-12-27 | ネステク ソシエテ アノニム | Oil-in-water emulsion for delivery |
JP2008154577A (en) * | 2006-12-01 | 2008-07-10 | Fujifilm Corp | Emulsified composition, and food and cosmetic containing the same |
JP2009189335A (en) * | 2008-02-18 | 2009-08-27 | Sanei Gen Ffi Inc | Carotenoid-containing emulsion composition and method for producing the same |
JP2012521774A (en) * | 2009-03-30 | 2012-09-20 | ビーエーエスエフ ソシエタス・ヨーロピア | Immediate use stable suspension of partially amorphous carotenoid particles |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5393123B2 (en) * | 2007-12-12 | 2014-01-22 | 富士フイルム株式会社 | External preparation for skin and method for producing the same |
-
2010
- 2010-05-10 JP JP2011540424A patent/JP5691037B2/en not_active Expired - Fee Related
- 2010-05-10 WO PCT/JP2010/057878 patent/WO2011058773A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002218994A (en) * | 2001-01-26 | 2002-08-06 | Fuji Chem Ind Co Ltd | Method for purifying crude xanthophyll |
JP2004035528A (en) * | 2002-07-08 | 2004-02-05 | Tropical Technology Center Ltd | Method for acquiring fucoxanthin and/or fucosterol |
WO2005054415A1 (en) * | 2003-12-02 | 2005-06-16 | Suntory Limited | Fat composition containing phospholipid and long-chain polyunsaturated fatty acid-supplying compound and food using the same |
JP2007538040A (en) * | 2004-05-18 | 2007-12-27 | ネステク ソシエテ アノニム | Oil-in-water emulsion for delivery |
WO2007079443A2 (en) * | 2006-01-03 | 2007-07-12 | The Texas A & M University System | Bioactive complex compositions and methods of use thereof |
JP2008154577A (en) * | 2006-12-01 | 2008-07-10 | Fujifilm Corp | Emulsified composition, and food and cosmetic containing the same |
JP2009209146A (en) * | 2006-12-01 | 2009-09-17 | Fujifilm Corp | Emulsion composition, and foods and cosmetics containing the emulsion composition |
JP2009189335A (en) * | 2008-02-18 | 2009-08-27 | Sanei Gen Ffi Inc | Carotenoid-containing emulsion composition and method for producing the same |
JP2012521774A (en) * | 2009-03-30 | 2012-09-20 | ビーエーエスエフ ソシエタス・ヨーロピア | Immediate use stable suspension of partially amorphous carotenoid particles |
Non-Patent Citations (2)
Title |
---|
JPN6014011708; 金沢和樹、日本食品科学工学会誌、平成20年4月15日発行、第55巻第4号、194頁 * |
JPN6014011709; V.G.Raneva, et al., Journal of Oleo Science, 2003, 52(7), pp347-352 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018512432A (en) * | 2015-04-13 | 2018-05-17 | アルガテクノロジーズ リミテッドAlgatechnologies Ltd. | Compositions containing carotenoids and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JPWO2011058773A1 (en) | 2013-03-28 |
WO2011058773A1 (en) | 2011-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5691037B2 (en) | Oily composition | |
Pereira et al. | Xanthophylls from the sea: algae as source of bioactive carotenoids | |
Sathasivam et al. | Microalgae metabolites: A rich source for food and medicine | |
Miyashita et al. | Nutraceutical characteristics of the brown seaweed carotenoid fucoxanthin | |
Merhan | The biochemistry and antioxidant properties of carotenoids | |
Mohamadnia et al. | Production of fucoxanthin by the microalga Tisochrysis lutea: A review of recent developments | |
AU752468B2 (en) | Lutein esters having high bioavailability | |
Herrero et al. | Screening for bioactive compounds from algae | |
Gille et al. | Microalgae as a potential source of carotenoids: Comparative results of an in vitro digestion method and a feeding experiment with C57BL/6J mice | |
Xie et al. | Production of three types of krill oils from krill meal by a three-step solvent extraction procedure | |
Song et al. | Effect of ultrasonic waves on the stability of all-trans lutein and its degradation kinetics | |
Yang et al. | Chemistry and biochemistry of dietary carotenoids: bioaccessibility, bioavailability and bioactivities | |
Mumu et al. | Fucoxanthin: A promising phytochemical on diverse pharmacological targets | |
McCauley et al. | Effects of nutrients and processing on the nutritionally important metabolites of Ulva sp.(Chlorophyta) | |
Pangestuti et al. | Seaweed-derived carotenoids | |
Hajare et al. | Extraction and quantification of antioxidant lutein from various plant sources | |
Jain et al. | Algal carotenoids: understanding their structure, distribution and potential applications in human health | |
Maoka et al. | Some biological functions of carotenoids in Japanese food | |
WO2008023283A2 (en) | Stabilized esters of lutein | |
Morón-Ortiz et al. | Ultrasound-assisted extraction of carotenoids from phytoene-accumulating Chlorella sorokiniana microalgae: Effect of milling and performance of the green biosolvents 2-methyltetrahydrofuran and ethyl lactate | |
Akram et al. | β-Carotene: beyond provitamin A | |
Kumar et al. | Squalene: bioactivity, extraction, encapsulation, and future perspectives | |
Ranga Rao | Production of astaxanthin from cultured green alga Haematococcus pluvialis and its biological activities | |
Mahendran et al. | Microalgae as a potential source of bioactive food compounds | |
Gustafson et al. | Pycnanthus angolensis: Bioactive compounds and medicinal applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140325 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140526 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5691037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |